Drug Type Bispecific antibody |
Synonyms anti-TIGIT/anti-PD-L1 bispecific antibody, HB-0036, HB0036 |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 25 Aug 2022 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 25 Aug 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 25 Aug 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | CN | 25 Aug 2022 | |
Solid tumor | IND Approval | CN | 18 Aug 2022 |
Phase 1/2 | 19 | jwxocbudil(pswhcptfvh) = ≥10% zhjufgcpri (cflikkmzoq ) View more | Positive | 24 May 2024 | |||